Five of the 18 patients with EGFR/ERBB2 ex20 ins/dup had no other mutations providing more evidence that EGFR/ERBB2 ex20 ins/dup was the oncogenic driver in this molecular subtype of NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.